Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 11, 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance.
April 8, 2025—Techcyte, Pramana, and Aiosyn, announced a collaboration to integrate AI-powered breast and kidney histopathology analysis directly into a digital pathology workflow.
April 4, 2025—Paige announced that the FDA has granted breakthrough device designation to Paige PanCancer Detect, an AI-assisted diagnostic application intended to assist pathologists in the detection of foci that are suspicious for cancer from multiple tissues and organs.
April 3, 2025—Pillar Biosciences announced it has received nationwide Medicare coverage by the Centers for Medicare and Medicaid Services for the OncoReveal CDx pan-cancer solid tumor in vitro diagnostic next-generation sequencing kit.
April 2, 2025—Werfen announced the commercialization of its ACL Top Family 70 series hemostasis testing systems in North America, following FDA 510(k) clearance and Health Canada licensure.
April 1, 2025—The U.S. District Court for the Eastern District of Texas ruled on March 31 in favor of the laboratory plaintiffs in the two consolidated cases challenging the validity of the Food and Drug Administration’s final rule on laboratory-developed tests.
March 31, 2025—Siemens Healthineers announced that its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it to be used as a companion diagnostic test for people receiving treatment with fitusiran (Qfitlia, Sanofi), a hemophilia therapy.
March 27, 2025—Techcyte announced the launch of Fusion, a standards-based, SaaS platform designed to unify anatomic and clinical pathology workflows.
March 21, 2025—Pramana and ARUP Laboratories announced a collaboration to digitize pathology slides and develop AI-powered algorithms to improve the assessment of bone marrow biopsies and address other diagnostic challenges in hematopathology.
March 20, 2025—Advanced Instruments, a subsidiary of Patricia Industries, announced the execution of a definitive agreement to acquire Nova Biomedical.
